{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:55:31Z","timestamp":1782896131237,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to describe perioperative chemotherapy patterns, granulocyte colony-stimulating factor (G-CSF) use, and febrile neutropenia (FN) status in patients with early breast cancer (EBC) using real-world data in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational study used anonymized claims data. The included patients were\u2009\u2265\u200918\u00a0years old, were female, and had breast cancer diagnosis and surgery records between January 2010 and April 2020. Measures included perioperative chemotherapy, G-CSF use (daily and primary prophylaxis [PP]), and FN and FN-related hospitalization (FNH), all examined annually. Perioperative chemotherapy was examined separately for human epidermal growth factor receptor 2-positive\/negative (HER2\u00b1). A multivariate logistic regression was used to explore the factors associated with FNH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 32,597 patients, those with HER2\u2009+\u2009EBC treated with anthracycline-based regimens followed by taxane\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab increased since 2018, and those with HER2\u00a0\u2212\u00a0EBC treated with doxorubicin\/epirubicin\u2009+\u2009cyclophosphamide followed by taxane and dose-dense regimens increased after 2014. The proportion of patients prescribed daily G-CSF declined after 2014, whereas that of pegfilgrastim PP increased. The incidence proportion of FN remained at approximately 24\u201331% from 2010 to 2020, while that of FNH declined from 14.5 to 4.0%. The odds of FNH were higher in those aged\u2009\u2265\u200965\u00a0years and lower with pegfilgrastim PP administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite the increasing use of escalated regimens in the last 5\u20136\u00a0years, FNH continuously declined, and the odds of FNH were lower among patients treated with pegfilgrastim PP. These results may suggest the contribution of PP in part to suppressing FNH levels over the last 5\u20136\u00a0years.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-07015-w","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T10:01:52Z","timestamp":1688637712000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-5098","authenticated-orcid":false,"given":"Nobuhiro","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-3353","authenticated-orcid":false,"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"7015_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","volume":"13","author":"J Anampa","year":"2015","unstructured":"Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 13:195. https:\/\/doi.org\/10.1186\/s12916-015-0439-8","journal-title":"BMC Med"},{"key":"7015_CR2","unstructured":"National Comprehensive Cancer Network (NCCN) (2022) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 4.2022. 21 June 2022. National Comprehensive Cancer Network. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 15 Dec 2022"},{"issue":"3","key":"7015_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12282-020-01085-0","volume":"27","author":"T Shimoi","year":"2020","unstructured":"Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M et al (2020) The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer 27(3):322\u2013331. https:\/\/doi.org\/10.1007\/s12282-020-01085-0","journal-title":"Breast Cancer"},{"key":"7015_CR4","doi-asserted-by":"publisher","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28(8):1700\u20131712. https:\/\/doi.org\/10.1093\/annonc\/mdx308","DOI":"10.1093\/annonc\/mdx308"},{"issue":"10","key":"7015_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P et al (2019) Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30(10):1541\u20131557. https:\/\/doi.org\/10.1093\/annonc\/mdz235","journal-title":"Ann Oncol"},{"issue":"3","key":"7015_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12282-019-01039-1","volume":"27","author":"T Yoshinami","year":"2020","unstructured":"Yoshinami T, Koizumi K, Nagai SE, Toyama T, Iwata H (2020) Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition. Breast Cancer 27(3):334\u2013339. https:\/\/doi.org\/10.1007\/s12282-019-01039-1","journal-title":"Breast Cancer"},{"issue":"2","key":"7015_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"key":"7015_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"key":"7015_CR9","unstructured":"KYOWA KIRIN Co. Ltd. (2022) G-LASTA\u00ae (pegfilgrastim) subcutaneous injection 3.6mg\/G-LASTA\u00ae subcutaneous injection 3.6 mg BodyPod. December 2022. (in Japanese). Available from: https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/230124_3399410G1020_1_019_1F.pdf. Accessed 16 Dec 2022"},{"key":"7015_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2021.01.005","volume":"56","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T, Tamaki K et al (2021) Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. Breast 56:70\u201377. https:\/\/doi.org\/10.1016\/j.breast.2021.01.005","journal-title":"Breast"},{"key":"7015_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency (2018) New drugs approved in FY 2018 (April 2018-March 2019). Available from: https:\/\/www.pmda.go.jp\/files\/000235288.pdf. Accessed 26 Aug 2022"},{"issue":"9980","key":"7015_CR12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/s0140-6736(14)62048-1","volume":"385","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863\u20131872. https:\/\/doi.org\/10.1016\/s0140-6736(14)62048-1","journal-title":"Lancet"},{"issue":"3","key":"7015_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10549-021-06417-y","volume":"193","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L et al (2022) Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Res Treat 193(3):555\u2013564. https:\/\/doi.org\/10.1007\/s10549-021-06417-y","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7015_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/jco.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177\u20131183. https:\/\/doi.org\/10.1200\/jco.2008.18.4028","journal-title":"J Clin Oncol"},{"key":"7015_CR15","unstructured":"Japan Society of Clinical Oncology (2018) Clinical practice guidelines for the proper use of granulocyte colony-stimulating factor 2013 (version 5). (in Japanese).  http:\/\/jsco-cpg.jp\/item\/30\/index.html. Accessed 26 Aug 2022"},{"issue":"28","key":"7015_CR16","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"12","key":"7015_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","volume":"15","author":"J Crawford","year":"2017","unstructured":"Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P et al (2017) Myeloid growth factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(12):1520\u20131541. https:\/\/doi.org\/10.6004\/jnccn.2017.0175","journal-title":"J Natl Compr Canc Netw"},{"key":"7015_CR18","unstructured":"Pharmacoepidemiology & Database Task Force (2022) Japanese Society for Pharmacoepidemiology, Survey of Japanese databases in Japan available for clinical\/pharmacoepidemiology (as of August 2022). https:\/\/www.jspe.jp\/mt-static\/FileUpload\/files\/JSPE_DB_TF_E.pdf. Accessed 21 Nov 2022."}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07015-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T20:29:50Z","timestamp":1689971390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07015-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["7015"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07015-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nobuhiro Shibata reports consulting or advisory roles for Kyowa Kirin Co., Ltd.; has received speaker\u2019s bureau from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., MSD K.K., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., and Becton, Dickinson and Company; and has received research funding from Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and MSD K.K. Tetsuhiro Yoshinami has received speaker honoraria from Kyowa Kirin Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Kentaro Tamaki has no competing interest to declare. Tomoyuki Nukada is an employee of Kyowa Kirin Co., Ltd. Shinji Ohno has received speaker honoraria from Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku Co., Ltd., and Chugai Pharmaceutical Co., Ltd. and received grants from Eisai Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Research Institute of Healthcare Data Science (RI2021015). According to the \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects\u201d, a study using secondary data stored in an anonymized structured format, such as this study, is outside the scope of the guidelines. Informed consent was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}